Avilés-Rosas V H, Rivera-Mancilla E, Marichal-Cancino B A, Manrique-Maldonado G, Altamirano-Espinoza A H, Maassen Van Den Brink A, Villalón C M
Departamento de Farmacobiología, Cinvestav-Coapa, México D.F., Mexico.
Department of Internal Medicine, Division of Pharmacology, Vascular and Metabolic Diseases, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands.
Br J Pharmacol. 2017 Jul;174(13):2001-2014. doi: 10.1111/bph.13799. Epub 2017 May 2.
Olcegepant (BIBN4096BS) is a selective non-peptide CGRP receptor antagonist with acute antimigraine properties. Since systemic vascular tone is modulated by perivascular (primary sensory CGRPergic and sympathetic) nerves, this randomized study investigated in pithed rats the effect of acute i.v. treatment with olcegepant on the neurogenic and non-neurogenic: (i) CGRPergic vasodepressor responses; and (ii) noradrenergic vasopressor responses. The pithed rat is an experimental model predictive of systemic (cardio) vascular side effects.
Seventy-five male Wistar rats (divided into 15 groups, n = 5 each) were pithed, artificially ventilated and prepared for: (i) spinal stimulation (T -T ; 0.56-5.6 Hz) of the sensory CGRPergic vasodepressor outflow or i.v. bolus injections (0.1-1 μg·kg ) of α-CGRP, substance P or acetylcholine, which induced frequency-dependent or dose-dependent vasodepressor responses; or (ii) spinal stimulation (T -T ; 0.03-3 Hz) of the sympathetic vasopressor outflow or i.v. bolus injections (0.03-3 μg·kg ) of noradrenaline, which produced frequency-dependent or dose-dependent vasopressor responses.
Olcegepant (1000 and 3000 μg·kg , i.v.) dose-dependently blocked the vasodepressor responses to sensory nerve stimulation or i.v. α-CGRP, without affecting those to substance P or acetylcholine. Whereas it potentiated the vasopressor responses to sympathetic nerve stimulation or i.v. noradrenaline.
Olcegepant (i.v.) selectively blocked the neurogenic and non-neurogenic CGRPergic vasodepressor responses. This blockade by olcegepant potentiated the neurogenic and non-neurogenic noradrenergic vasopressor responses in pithed rats, an effect that might result in an increased vascular resistance and, consequently, in a prohypertensive action.
olcegepant(BIBN4096BS)是一种具有急性抗偏头痛特性的选择性非肽类降钙素基因相关肽(CGRP)受体拮抗剂。由于全身血管张力受血管周围(初级感觉CGRP能和交感)神经调节,本随机研究在脊髓横断大鼠中研究了olcegepant急性静脉注射对神经源性和非神经源性的影响:(i)CGRP能血管舒张反应;以及(ii)去甲肾上腺素能血管收缩反应。脊髓横断大鼠是一种可预测全身(心脏)血管副作用的实验模型。
75只雄性Wistar大鼠(分为15组,每组n = 5)进行脊髓横断、人工通气,并准备用于:(i)对感觉CGRP能血管舒张传出神经进行脊髓刺激(T -T ;0.56 - 5.6 Hz)或静脉推注(0.1 - 1 μg·kg )α-CGRP、P物质或乙酰胆碱,可诱导频率依赖性或剂量依赖性血管舒张反应;或(ii)对交感血管收缩传出神经进行脊髓刺激(T -T ;0.03 - 3 Hz)或静脉推注(0.03 - 3 μg·kg )去甲肾上腺素,可产生频率依赖性或剂量依赖性血管收缩反应。
olcegepant(1000和3000 μg·kg ,静脉注射)剂量依赖性地阻断了对感觉神经刺激或静脉注射α-CGRP的血管舒张反应,而不影响对P物质或乙酰胆碱的反应。而它增强了对交感神经刺激或静脉注射去甲肾上腺素的血管收缩反应。
olcegepant(静脉注射)选择性地阻断了神经源性和非神经源性CGRP能血管舒张反应。olcegepant的这种阻断作用增强了脊髓横断大鼠的神经源性和非神经源性去甲肾上腺素能血管收缩反应,这种效应可能导致血管阻力增加,进而产生升压作用。